Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138485

Published: 2020

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Issam S. Hamadeh, PharmD, Justin Arnall, Pharm.D., Ekaterina Kachur, PharmD, Allison Martin, PharmD, Megan Helena Jagosky, MD, Reed Friend, MD, Shebli Atrash, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2018-99-118737

Published: 2018

Journal Articles

Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma

Myra M Robinson, MSPH, Shebli Atrash, Taylor Brown, BS, MS, Jared G Block, MD, Edward H Lipford, MD, Elton T Smith, MD, Reed Friend, MD, Amanda Aneralla, Alankrita Taneja, MD, Qing Zhang, PhD, David M Foureau, PhD, Chelsea Sprouse, Ami Ndiaye, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD, Manisha Bhutani, MD

Blood (2017) 130 (Supplement 1): 4348.

https://doi.org/10.1182/blood.V130.Suppl_1.4348.4348

Published: 2017

Journal Articles

Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

David M Foureau, PhD, Manisha Bhutani, MD, Qing Zhang, PhD, Myra M Robinson, MSPH, Adina Wynn, Nury M Steuerwald, PhD, Lawrence J Druhan, PhD, Fei Guo, PhD, Katherine Rigby, Mitchell Turner, Reed Friend, MD, Shebli Atrash, Chelsea Sprouse, Ami Ndiaye, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 1817.

https://doi.org/10.1182/blood.V130.Suppl_1.1817.1817

Published: 2017

Journal Articles

Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma

Shebli Atrash, Myra M Robinson, MSPH, Amanda Aneralla, Taylor Brown, BS, MS, Reed Friend, MD, Chelsea Sprouse, Ami Ndiaye, Qing Zhang, PhD, Edward H Lipford, MD, Jared G Block, MD, Elton T Smith, MD, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD, Manisha Bhutani, MD

Blood (2017) 130 (Supplement 1): 1779.

https://doi.org/10.1182/blood.V130.Suppl_1.1779.1779

Published: 2017

Journal Articles

Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases

Manisha Bhutani, MD, David M Foureau, PhD, Qing Zhang, PhD, Myra M Robinson, MSPH, Adina Wynn, Nury M Steuerwald, PhD, Lawrence J Druhan, PhD, Fei Guo, PhD, Katherine Rigby, Mitchell Turner, Reed Friend, MD, Shebli Atrash, Ami Ndiaye, Chelsea Sprouse, James T Symanowski, PhD, Belinda Rene Avalos, MD, Edward A Copelan, MD, Peter M. Voorhees, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 3054.

https://doi.org/10.1182/blood.V130.Suppl_1.3054.3054

Published: 2017

Journal Articles

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Reed Friend, MD, Ridas Juskevicius, MD, Lauren Salmon, DO, Hemant S. Murthy, MD, James Xenakis, Adam S. Asch, MD, Paul Walker, MD

Blood (2015) 126 (23): 3783.

https://doi.org/10.1182/blood.V126.23.3783.3783

Published: 2015

Journal Articles

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

Reed Friend, MD, James Xenakis, Jonathan S Serody, MD, Terrance Comeau, MD, Don A. Gabriel, MD PhD, Stefanie Sarantopoulos, MD PhD, James Coghill, MD, William A. Wood, MD MPH, Andrew Sharf, Julia S Whitley, BS, Kamakshi Rao, PharmD, Christine M Walko, PharmD,BCOP, Anastasia Ivanova, PhD, Thomas C. Shea, MD, Paul M Armistead, MD PhD

Blood (2015) 126 (23): 3117.

https://doi.org/10.1182/blood.V126.23.3117.3117

Published: 2015

NARROW

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma

Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma

Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only